论文部分内容阅读
本文报道了对有严重青光眼和哮喘患者禁用噻吗洛尔或以前曾使肺部病情加重的患者研究应用倍他索洛尔的疗效。患者11例均有明显的视野缺损、视盘凹陷和高眼压,虽用最大剂量药物也不能控制。8例过去曾用过倍他索洛尔,因用药后肺部病情加重或发生并发症而中断用药。9例原发开角型青光眼,1例假性剥脱性青光眼,1例曾做过虹膜切除术的混合型青光眼。11例病人均患呼吸道疾病,最大肺活量(FVC)、每秒钟最大呼吸容量(FEV_1)和两者之比用来作为选择病人的基本读数。FEV_1/FVC值小于40%者均除外。用0.5%倍他索洛尔点患者双眼,每次1滴,一天2次,第一滴由检查者执行,观察4小时,持续用药2～3周复查、同时复查肺功能。
This article reports the efficacy of betaxololol in patients with severe glaucoma and asthma who have been banned from timolol or who had previously exacerbated the lung condition. Eleven patients had obvious visual field defects, optic disc depression and ocular hypertension, although the maximum dose of medication can not be controlled. Eight patients had used betaxololol in the past, discontinuing medication due to exacerbation or complications of the lungs after treatment. 9 cases of primary open-angle glaucoma, 1 case of pseudo-exfoliative glaucoma, and 1 case of glaucoma that had undergone iridectomy. Eleven patients had respiratory disease, maximum vital capacity (FVC), maximum respiratory capacity per second (FEV_1), and the ratio of the two used as a baseline reading for patient selection. Except FEV_1 / FVC less than 40%. Patients with 0.5% beta sotalol binocular eyes, each drop of 1, 2 times a day, the first drop by the examiner to perform, observed 4 hours, continued treatment for 2 to 3 weeks review, at the same time review of lung function.